A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC
Marzia Del Re(Saint Camillus International University of Health and Medical Sciences), Romano Danesi(University of Milan), Iacopo Petrini(University of Pisa), G. Pasquini(Istituto Nazionale di Fisica Nucleare, Sezione di Bologna), Raffaele Ciampi(University of Pisa), Camillo Porta(University of Pavia), Mimma Rizzo(University of Pavia), Nicole Gri(Istituti Clinici Scientifici Maugeri), Lorenzo Fontanelli(University of Pisa), Stefania Crucitta(Meyer Children's Hospital), Michela Gabelloni(University of Pisa), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Lorenzo Belluomini(University of Ferrara), Federico Cucchiara(University of Pisa), Emanuele Neri(University of Pisa), Eleonora Rofi(University of Pisa)
Cited by 38
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan
|JAMA Oncology|2018|418